US FDA Approves Werfen's New Aptiva® Reagents for Antiphospholipid Syndrome

Werfen has received 510(k) clearance from the US Food and Drug Administration (FDA) for its Aptiva® Antiphospholipid Syndrome (APS) Immunoglobulin G (IgG) and Immunoglobulin M (IgM) Reagents.

These immunoassays use Aptiva's particle-based multi-analyte technology (PMAT) to semi-quantitatively determine anti-cardiolipin (aCL) and anti-beta 2 glycoprotein 1 (aβ2GP1) IgG and IgM in human serum.

They assist in diagnosing both primary and secondary APS when used alongside other laboratory and clinical findings.

APS is known for its complex symptoms, which can resemble other conditions, making diagnosis challenging. The clearance of these reagents supports improved diagnostic accuracy for autoimmune diseases.

By providing comprehensive data, they help healthcare professionals make informed decisions, ultimately reducing misdiagnosis and improving patient outcomes.

The Aptiva system is a next-generation, fully automated platform designed for autoimmune laboratories. It employs PMAT technology to deliver up to 960 test results in an eight-hour shift, enabling high-throughput testing with minimal manual intervention.

With this latest approval, Werfen expands its Aptiva portfolio, which already includes reagents for Celiac Disease and Connective Tissue Diseases (CTD). The portfolio now comprises 18 FDA-cleared analytes.

Future developments will further extend the Aptiva range to cover additional autoimmune disease markers. Over 60 analytes are currently in different stages of development, reinforcing Werfen's commitment to advancing autoimmune disease diagnostics and enhancing patient care.